Literature DB >> 15909288

Application of hidden Markov models to multiple sclerosis lesion count data.

Rachel MacKay Altman1, A John Petkau.   

Abstract

This paper is motivated by the work of Albert et al. who consider lesion count data observed on multiple sclerosis patients, and develop models for each patient's data individually. From a medical perspective, adequate models for such data are important both for describing the behaviour of lesions over time, and for designing efficient clinical trials. In this paper, we discuss some issues surrounding the hidden Markov model proposed by these authors. We describe an efficient estimation method and propose some extensions to the original model. Our examples illustrate the need for models which describe all patients' data simultaneously, while allowing for inter-patient heterogeneity. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15909288     DOI: 10.1002/sim.2108

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified.

Authors:  Julia S Benoit; Wenyaw Chan; Sheng Luo; Hung-Wen Yeh; Rachelle Doody
Journal:  Stat Med       Date:  2016-01-18       Impact factor: 2.373

2.  Bayesian hidden Markov models for delineating the pathology of Alzheimer's disease.

Authors:  Kai Kang; Jingheng Cai; Xinyuan Song; Hongtu Zhu
Journal:  Stat Methods Med Res       Date:  2017-12-26       Impact factor: 3.021

3.  Qualitative longitudinal analysis of symptoms in patients with primary and metastatic brain tumours.

Authors:  Frank Rijmen; Edward H Ip; Stephen Rapp; Edward G Shaw
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2008       Impact factor: 2.483

4.  Hidden Markov models for zero-inflated Poisson counts with an application to substance use.

Authors:  Stacia M DeSantis; Dipankar Bandyopadhyay
Journal:  Stat Med       Date:  2011-05-02       Impact factor: 2.373

5.  Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Authors:  Kumar Kandadi Muralidharan; Deb Steiner; Diogo Amarante; Pei-Ran Ho; Dan Mikol; Jacob Elkins; Meena Subramanyam; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-01       Impact factor: 2.745

6.  Partially hidden Markov model for time-varying principal stratification in HIV prevention trials.

Authors:  James Y Dai; Peter B Gilbert; Benoît R Mâsse
Journal:  J Am Stat Assoc       Date:  2012-03-01       Impact factor: 5.033

7.  Epilepsy as a dynamic disease: A Bayesian model for differentiating seizure risk from natural variability.

Authors:  Sharon Chiang; Marina Vannucci; Daniel M Goldenholz; Robert Moss; John M Stern
Journal:  Epilepsia Open       Date:  2018-04-20

8.  Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.

Authors:  Yaming Hang; Xiao Hu; Jie Zhang; Shifang Liu; Aaron Deykin; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-06-14       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.